Health & Environmental Research Online (HERO)


Print Feedback Export to File
2850125 
Journal Article 
Identification of chemical modulators of the constitutive activated receptor (CAR) in a gene expression compendium 
Oshida, K; Vasani, N; Jones, C; Moore, T; Hester, S; Nesnow, S; Auerbach, S; Geter, DR; Aleksunes, LM; Thomas, RS; Applegate, D; Klaassen, CD; Corton, JC 
2015 
Yes 
Nuclear Receptor Signaling
ISSN: 1550-7629 
13 
e002 
English 
The nuclear receptor family member constitutive activated receptor (CAR) is activated by structurally diverse drugs and environmentally-relevant chemicals leading to transcriptional regulation of genes involved in xenobiotic metabolism and transport. Chronic activation of CAR increases liver cancer incidence in rodents, whereas suppression of CAR can lead to steatosis and insulin insensitivity. Here, analytical methods were developed to screen for chemical treatments in a gene expression compendium that lead to alteration of CAR activity. A gene expression biomarker signature of 83 CAR-dependent genes was identified using microarray profiles from the livers of wild-type and CAR-null mice after exposure to three structurally-diverse CAR activators (CITCO, phenobarbital, TCPOBOP). A rank-based algorithm (Running Fisher's algorithm (p-value ≤ 10(-4))) was used to evaluate the similarity between the CAR biomarker signature and a test set of 28 and 32 comparisons positive or negative, respectively, for CAR activation; the test resulted in a balanced accuracy of 97%. The biomarker signature was used to identify chemicals that activate or suppress CAR in an annotated mouse liver/primary hepatocyte gene expression database of ~1850 comparisons. CAR was activated by 1) activators of the aryl hydrocarbon receptor (AhR) in wild-type but not AhR-null mice, 2) pregnane X receptor (PXR) activators in wild-type and to lesser extents in PXR-null mice, and 3) activators of PPARα in wild-type and PPARα-null mice. CAR was consistently activated by five conazole fungicides and four perfluorinated compounds. Comparison of effects in wild-type and CAR-null mice showed that the fungicide propiconazole increased liver weight and hepatocyte proliferation in a CAR-dependent manner, whereas the perfluorinated compound perfluorooctanoic acid (PFOA) increased these endpoints in a CAR-independent manner. A number of compounds suppressed CAR coincident with increases in markers of inflammation including acetaminophen, concanavalin A, lipopolysaccharide, and 300 nm silica particles. In conclusion, we have shown that a CAR biomarker signature coupled with a rank-based similarity method accurately predicts CAR activation. This analytical approach, when applied to a gene expression compendium, increased the universe of known chemicals that directly or indirectly activate CAR, highlighting the promiscuous nature of CAR activation and signaling through activation of other xenobiotic-activated receptors. 
PFAS
• Additional PFAS (formerly XAgency)
     Literature Search November 2019
          Other Sources
               TEDX
     Screened Studies
          Excluded
               Exclude (TIAB)
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          Other Sources
               PFAS TOX Database
     Screened Studies
          Excluded
               Exclude (TIAB)
• ^Per- and Polyfluoroalkyl Substances (PFAS)
     PFOA (335-67-1) and PFOS (1763-23-1)
          Literature Search – Adverse outcome pathway (2015-present)
               Pubmed
• PFAS 150
     Literature Search Update December 2020
          PubMed
     Literature Search August 2019
          PubMed
          Other sources
               PFAS TOX Database
     Not prioritized for screening
     Ammonium perfluorooctanoate
     Perfluorinated compounds
     Perfluorooctanoic acid
• PFAS Universe
     Data Source
          Pubmed
     Perfluorooctanoate
• PFHxS
     Database searches
          Pelch PFAS SEM
     Excluded
          TiAb
• PFNA
     June 2022 Pelch Database
• PFOA (335-67-1) and PFOS (1763-23-1)
     Literature Search – Adverse outcome pathway (2015-present)
          Pubmed
     Screening Results
          In vitro/ex vivo/in silico
               Receptor activation
     Literature Search Update (2013-2019)
          PubMed
• Yale PFAS Liver study